Mobile

A clinical study to evaluate the safety and benefit from using Everolimus and Exemestane in combination in postmenopausal women with estrogen receptor positive breast cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-006111-62

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To assess the Overall Response Rate (ORR) in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus and Exemestane.

Critère d'inclusion

  • The trial aims to evaluate the efficacy, safety, quality of life and health resources in postmenopausal women with hormone receptor positive breast cancer progressing following prior therapy with NSAIs treated with the combination of Everolimus and Exemestane

Liens